Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isa Mambetsariev

Showing results (61-70 of 78) with videos related to

Pageof 8
Sort By:
Cancers|November 27, 2025
Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative ReviewDouglas Dias E Silva, Beatriz Viesser Miyamura, Isa Mambetsariev, et al.
Cancers|October 14, 2022
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
Frontiers in Oncology|May 12, 2020
Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic ApproachBihong T Chen, Zikuan Chen, Ningrong Ye, et al.
NPJ Precision Oncology|June 19, 2024
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcomeDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
NPJ Precision Oncology|October 29, 2025
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatmentKevin Lu, John Paul Shen, Fernando J Lopez-Diaz, et al.
Journal of Clinical Medicine|October 23, 2019
Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRASArjun Kalvala, Pierre Wallet, Lu Yang, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Iscience|September 18, 2020
A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung CancerAtish Mohanty, Arin Nam, Alex Pozhitkov, et al.
Oncogenesis|September 6, 2019
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesotheliomaYi-Hung Carol Tan, Saumya Srivastava, Brian M Won, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, et al.
Pageof 8

Showing results (61-70 of 78) with videos related to

Sort By:
Pageof 8
Cancers|November 27, 2025
Current Clinical Paradigm and Therapeutic Advancements in Thymic Malignancies: A Narrative ReviewDouglas Dias E Silva, Beatriz Viesser Miyamura, Isa Mambetsariev, et al.
Cancers|October 14, 2022
Clinical and Molecular Features of KRAS-Mutated Lung Cancer Patients Treated with Immune Checkpoint InhibitorsDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
Frontiers in Oncology|May 12, 2020
Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic ApproachBihong T Chen, Zikuan Chen, Ningrong Ye, et al.
NPJ Precision Oncology|June 19, 2024
Spatial iTME analysis of KRAS mutant NSCLC and immunotherapy outcomeDan Zhao, Haiqing Li, Isa Mambetsariev, et al.
NPJ Precision Oncology|October 29, 2025
Diversity of BRAF mutations in non-small cell lung cancer and implications on treatmentKevin Lu, John Paul Shen, Fernando J Lopez-Diaz, et al.
Journal of Clinical Medicine|October 23, 2019
Phenotypic Switching of Naïve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRASArjun Kalvala, Pierre Wallet, Lu Yang, et al.
Future Science OA|January 13, 2021
Co-stimulatory and co-inhibitory immune markers in solid tumors with <i>MET</i> alterationsKaren L Reckamp, Jasmine A McQuerry, Isa Mambetsariev, et al.
Iscience|September 18, 2020
A Non-genetic Mechanism Involving the Integrin β4/Paxillin Axis Contributes to Chemoresistance in Lung CancerAtish Mohanty, Arin Nam, Alex Pozhitkov, et al.
Oncogenesis|September 6, 2019
EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesotheliomaYi-Hung Carol Tan, Saumya Srivastava, Brian M Won, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 15, 2021
Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive ChemoradiotherapyJacqueline V Aredo, Isa Mambetsariev, Jessica A Hellyer, et al.
Pageof 8